Pharmacyte Biotech Inc (OTCMKTS:PMCB) was at $0.0984, showing a -0.10% decrease. Around 1.43 million shares have been traded, versus an-average trading volume of 2.30 million shares.

Pharmacyte Biotech Inc (PMCB) on April 3, 2017 announced the appointment of Mark L. Rabe, MD, as Director of Cannabis Program Development. In his new role, Dr. Rabe will be tasked with leading strategic planning, management and development of PharmaCyte’s Cell-in-a-Box® cannabinoid-based therapy, which is currently in the preclinical research phase. He will also provide operational support to the Chief Executive Officer and executive management team. Dr. Rabe will continue as a member of PharmaCyte’s Medical and Scientific Advisory Board.

PharmaCyte has a license to utilize the Cell-in-a-Box technology with cannabinoids (constituents of Cannabis) to treat diseases and their related symptoms. PharmaCyte’s “Cannabis Therapy Program” is currently focused on bio-engineering a human cell line that is suitable for Cell-in-a-Box® live-cell encapsulation and capable of producing an enzyme to convert a cannabinoid “prodrug” into its active cancer-killing form. This research seeks to leverage the documented anti-cancer properties of cannabinoid molecules, such as THC (tetrahydrocannabinol) and CBD (cannabidiol).

“We are very pleased to expand Dr. Rabe’s presence at PharmaCyte,” commented PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner. “Dr. Rabe has been superlative in his role as a member of our Medical and Scientific Advisory Board, and now he will be leading our efforts to develop and/or license a marketable Cell-in-a-Box/cannabinoid therapy. His impressive background in operations, management and educational content development–in addition to his experience as a physician–will also be quite helpful in our planned pivotal clinical trial involving locally-advanced, non-metastatic pancreas cancer.”

Growlife Inc (OTCMKTS:PHOT) shares today, losing 4.00 per cent to $0.00960. Around 8.89M shares changed hands so far in this session compared to an-average trading volume of 12.86 million shares.

Growlife Inc (PHOT) on February 15, 2017 announced the expansion of its Board of Directors and management team.

As GrowLife seeks to capitalize on the increasing demand for indoor cultivation by commercial growers as well as consumers, along with the recent announcement of GrowLife’s Retail License Program, it has added two experienced executives to its board of directors: Ms. Katherine McLain, corporate counsel for Stripe and the return to the Board of Mr. Mark Scott, GrowLife CFO.

“Our new board members strengthen the GrowLife bench and deepen the resources across finance, legal and operations,” stated Mr. Marco Hegyi, GrowLife Chairman and CEO. “Katherine brings Silicon Valley legal knowledge and banking expertise from Stripe and Silicon Valley Bank, and Mark rejoins the board and adds a second executive board member perspective.” Their brief biographies are listed below.

In addition, Mr. Darren Erasmus, a well-respected cultivation industry leader from House & Garden Nutrients, has joined the Company as its National Sales Manager.

“Darren’s wealth of experience and unparalleled network is a powerful and critical addition to GrowLife,” continued Mr. Hegyi. “He will help Joe Barnes, Senior Vice-president of Business Development, build our Sales team, GrowLife’s focus on nationwide revenue expansion, and recruit stores into the GrowLife Retail License Program.”

Earth Science Tech Inc (OTCMKTS:ETST) was trading lower by -1.18% to $1.68. So far, around 12,889.00 shares have changed hands in this session. After opening at $1.70, the stock hit as high as $3.95. However, it traded between $1.60 and $1.70 over the last twelve months.

On March 6, 2017 Earth Science Tech, Inc. (ETST), an innovative biotech company focused on cannabis (industrial hemp) and cannabinoid research and development, nutraceuticals, pharmaceuticals, and medical devices based company is proud to announce that its wholly owned subsidiary Cannabis Therapeutics timeline for its cannabis cannabinoid-based nutraceutical patent and generic pharmaceutical drug completion.

At a meeting with the company’s Advisory Board on Tuesday, February 28th at Le Centre Québecois d’Innovation en Biotechnologie (CQIB) in Laval, Québec; the scientists concluded that the improved CBD Hemp Oil food supplement was ready to move to prototyping, and then to be fast tracked to commercialization. In addition, two cannabinoid-based generic pharmaceutical drugs will be ready for pre-market clinical trials related to drug bioavailability by Q3 2017. Depending on the time needed to properly conduct the clinical trials, both of the pharmaceutical drugs looks to be completed by the end of 2017 or beginning of 2018.

The first or these two generic drugs, an anti-breast cancer drug, is an important advance for the company as breast cancer affects more women worldwide than any other cancer. The components of the anti-breast cancer drug that Cannabis Therapeutics is bringing to market are contained in the World Health Organization’s current Model List of Essential Medicines (2015). The WHO Model Complementary List indicates the essential medicines needed to treat priority diseases, such as breast cancer, by any healthcare system.